Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

170.69
+2.811.67%
Post-market: 170.65-0.0400-0.02%19:30 EDT
Volume:1.92M
Turnover:324.20M
Market Cap:22.91B
PE:-48.72
High:170.85
Open:167.25
Low:165.01
Close:167.88
52wk High:176.58
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.71
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-102.78
PE(LYR):-51.41

Loading ...

Movement Alert|Guardant Health Rises 5.26% in Regular Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines

Market Focus
·
May 28

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid S&P 500, Nasdaq Rally, Middle East Peace Optimism

MT Newswires Live
·
May 27

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live
·
May 27

Guardant Health Says Shield Blood Test Included in American Cancer Society Guidelines

MT Newswires Live
·
May 27

Guardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap

Simply Wall St.
·
May 27

Guardant Health Chief Commercial Officer Chris Freeman disposes of 24,406 common shares worth $2.9 million

Reuters
·
May 27

Guardant Health Is Maintained at Buy by BTIG

Dow Jones
·
May 26

Guardant Health Inc : Btig Raises Target Price to $155 From $145

THOMSON REUTERS
·
May 26

Assessing Guardant Health (GH) Valuation After A Strong Share Price Run

Simply Wall St.
·
May 24

Guardant Health Chief Legal Officer John G. Saia sells USD 2.11 million common shares

Reuters
·
May 23

Guardant Health Co-CEO AmirAli Talasaz disposes of shares worth $22.18 million

Reuters
·
May 23

Guardant Health director Ian T. Clark disposes of shares worth $735,048.53

Reuters
·
May 23

Guardant Health director Manuel Hidalgo Medina disposes 1,250 shares worth $133,384.38

Reuters
·
May 23

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

GlobeNewswire
·
May 23

Movement Alert|Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally

Market Focus
·
May 22

Movement Alert|Guardant Health Rises 5.01% in Regular Trading, Liquid Biopsy Test Receives FDA Approval

Market Focus
·
May 21

GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026

TIPRANKS
·
May 21

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and OS Therapies Incorporated (OSTX)

TIPRANKS
·
May 21

Movement Alert|Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test

Market Focus
·
May 21

FDA approves Guardant360 Liquid CDx test for Guardant Health

Reuters
·
May 20